Blood -- Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy

Blood, Vol. 113, Issue 3, 538-545, January 15, 2009

Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector–mediated gene therapy
Blood Velazquez et al. 113: 538

Supplemental materials for: Velazquez et al

Files in this Data Supplement:

Figure S1. Phenotype analysis of splenic eGFP-specific CD8⁺ T cells (JPG, 88.4 KB) -
(A) At day 15 after rAAVeGFP (upper panel) or rAdeGFP (lower panel) administration, splenocytes were co-stained with the eGFP_200-208 tetramer and antibodies to CD8, CD62L, CD127 and CD43 activation associated glycoform. Numbers represent percentage of tetramer-positive CD8⁺ T cells that stain positive for each cell surface molecule. Gated as in Figure 2A. Data represent 2 independent experiments each with 5 pooled animals group.